English Finnish
Published: 2017-08-22 12:55:00 CEST
Biohit Oyj
Managers' Transactions

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, August 22, 2017 at 1:55 pm local time (EEST)

 

Biohit Oyj has received the following notification.

 

Person subject to the notification requirement
Name: Korpela, Semi  
Position: Chief Executive Officer
     
Initial Notification  
Reference number: 74370089ATTSNBXJVT29_20170822112601_8
     
Issuer
Name: Biohit Oyj
LEI: 74370089ATTSNBXJVT29
     
Transaction details
Transaction date: 2017-08-17
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Exercise (Rights, Put and Call Options)
Further details:  
  Linked to stock option programme
 
Instrument: Financial Instrument Linked to a Share or a Debt Instrument
ISIN: FI4000219324
 
Volume: 32274
Unit price: 3,16770 Euro
 
Aggregated transactions
Volume: 32274
Volume weighted average price: 3.16770 Euro
     
Transaction details
Transaction date: 2017-08-17
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Subscription
Further details:  
  Linked to stock option programme
 
Instrument: Financial Instrument Linked to a Share or a Debt Instrument
ISIN: FI4000219324
 
Volume: 7726
Unit price: 2,27660 Euro
 
Aggregated transactions
Volume: 7726
Volume weighted average price: 2.27660 Euro
     
Transaction details
Transaction date: 2017-08-17
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Disposal
Further details:  
  Linked to stock option programme
 
Instrument: Financial Instrument Linked to a Share or a Debt Instrument
ISIN: FI4000219324
 
Volume: 7726
Unit price: 0,00000 Euro
 
Aggregated transactions
Volume: 7726
Volume weighted average price: 0.00000 Euro

  

Additional information: 

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com